Prevenar (13v) Infant Drug Use Investigation

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Heptavalent Pneumococcal Conjugate Vaccine

Criteria

Inclusion Criteria:

• Vaccinees who meet all of the following conditions at the time of the first vaccination among infants who use Prevenar 13 in accordance with the indication, and dosage and administration of the vaccine will be included in the investigation:

• Infants aged 2 months, inclusive, to 7 months, exclusive

• Infants with no history of administration of pneumococcal vaccines including Prevenar 13

• Infants expected to receive 4 vaccinations

Exclusion Criteria:

• Vaccines must not be performed if the vaccinee corresponds to any of the following:

• Persons in whom a past history of anaphylaxis due to an ingredient of Prevenar 13 or diphtheria toxoid is evident

• Persons with evident pyrexia

• Persons who evidently have serious acute diseases

• Besides the persons listed above, persons who are in a status inappropriate for immunization